Bristol-based EnsiliTech secured €5.2 million in Seed funding. Eos Advisory led the round, aiming to transform global biopharma transport. This EnsiliTech funding supports the company's mission to eliminate cold-chain reliance for life-saving medicines.
Founded in 2022, EnsiliTech developed patented Ensilication technology. This innovation stabilizes biopharmaceuticals, including vaccines and antibodies, at temperatures up to 50°C. Furthermore, it encapsulates delicate biological materials within a protective silica layer, preserving integrity during transit. Consequently, the silica shell disintegrates upon use, releasing the active medicine.
Revolutionizing Pharmaceutical Logistics
The global pharmaceutical industry faces an estimated €30 billion in annual losses from cold-chain failures. Traditional systems require constant refrigeration, leading to significant waste, especially in developing regions. EnsiliTech's solution therefore reduces supply-chain costs, minimizes drug waste, and lowers the environmental impact of distribution. This biotechnology innovation addresses a critical need.
The fresh capital will accelerate technology adoption. EnsiliTech plans team and infrastructure expansion, plus validation studies for manufacturing integration.
EnsiliTech previously raised €1.3 million in 2023. The startup also features a predominantly female-led R&D and executive team. HERmesa, an investor group supporting women-led companies, participated in this startup investment round. Competitors like Catalent, Lonza, and UPS Healthcare also explore advanced drug delivery or logistics methods.